Advances in Oncology, 2022

Neoadjuvant Chemotherapy for Nonmetastatic Breast Cancer: How Response Impacts Locoregional and Adjuvant Systemic Therapy Decision Making<br>Contemporary Multimodal Management of Primary Retroperitoneal Sarcomas<br>NTRK Inhibitors in Adult Patients with Solid Tumors<br>The Landscape of Personalized Medicine in Gynecologic Cancer<br>Geriatric Assessments: Tools for Every Oncologist to Stage the Aging When Caring for Older Adults with Cancer<br>Sentinel Lymph Node Sampling in Endometrial Cancers<br>Health Care Disparities in Gynecologic Oncology<br>Clinical Trials of Oncolytic Viruses in Glioblastoma<br>Circulating Tumor Cells and Cell-free Tumor DNA in Evaluation and Management of Gliomas: Current Evidence and Potential Future Clinical Use<br>Optimizing Hematopoietic Cellular Transplantation in Older Adults with Hematologic Malignancies<br>Moving Toward a Cure in Multiple Myeloma:Eradication of Measurable Residual Disease<br>Advances in Janus-Associated Kinase Inhibitor-Based Therapies for Philadelphia Chromosome–Negative Myeloproliferative Neoplasms<br>Deoxyribonucleic Acid Damage Response Defects: Clinical Implications and the Role of Poly-ADP Ribose Polymerase Inhibitors in Genitourinary Cancers and Beyond<br>Clinical Trial Considerations for Bladder Preservation in Muscle-Invasive Bladder Cancer<br>The Changing Demographics of Colorectal Cancer: Rising Incidence in Younger Individuals<br>Total Neoadjuvant Strategies for Locally Advanced Rectal Cancer